Sean G. Rudd Science for Life Laboratory, Department of Oncology-Pathology Karolinska Institutet Biography Publications Institution JoVE Articles Sean G. Rudd has not added a biography. If you are Sean G. Rudd and would like to personalize this page please email our Author Liaison for assistance. Publications Crystal Structures of NUDT15 Variants Enabled by a Potent Inhibitor Reveal the Structural Basis for Thiopurine Sensitivity The Journal of Biological Chemistry. Mar, 2021 | Pubmed ID: 33753169 Drug Synergy Scoring Using Minimal Dose Response Matrices BMC Research Notes. Jan, 2021 | Pubmed ID: 33468238 Development of a Chemical Probe Against NUDT15 Nature Chemical Biology. 10, 2020 | Pubmed ID: 32690945 MTH1 Inhibitor TH588 Disturbs Mitotic Progression and Induces Mitosis-Dependent Accumulation of Genomic 8-oxodG Cancer Research. 09, 2020 | Pubmed ID: 32312836 Cell Cycle Profiling Reveals Protein Oscillation, Phosphorylation, and Localization Dynamics Molecular & Cellular Proteomics : MCP. 04, 2020 | Pubmed ID: 32051232 Ribonucleotide Reductase Inhibitors Suppress SAMHD1 Ara-CTPase Activity Enhancing Cytarabine Efficacy EMBO Molecular Medicine. 03, 2020 | Pubmed ID: 31950591 Author Correction: Targeted NUDT5 Inhibitors Block Hormone Signaling in Breast Cancer Cells Nature Communications. Nov, 2019 | Pubmed ID: 31676755 Low-level Expression of SAMHD1 in Acute Myeloid Leukemia (AML) Blasts Correlates with Improved Outcome Upon Consolidation Chemotherapy with High-dose Cytarabine-based Regimens Blood Cancer Journal. 10, 2018 | Pubmed ID: 30341277 Nucleobase and Nucleoside Analogues: Resistance and Re-Sensitisation at the Level of Pharmacokinetics, Pharmacodynamics and Metabolism Cancers. Jul, 2018 | Pubmed ID: 30041457 Targeted NUDT5 Inhibitors Block Hormone Signaling in Breast Cancer Cells Nature Communications. 01, 2018 | Pubmed ID: 29343827 With Me or Against Me: Tumor Suppressor and Drug Resistance Activities of SAMHD1 Experimental Hematology. 08, 2017 | Pubmed ID: 28502830 SAMHD1 Protects Cancer Cells from Various Nucleoside-based Antimetabolites Cell Cycle (Georgetown, Tex.). Jun, 2017 | Pubmed ID: 28436707 SAMHD1 is a Barrier to Antimetabolite-based Cancer Therapies Molecular & Cellular Oncology. 2017 | Pubmed ID: 28401188 Targeting SAMHD1 with the Vpx Protein to Improve Cytarabine Therapy for Hematological Malignancies Nature Medicine. Feb, 2017 | Pubmed ID: 28067901 Pathways Controlling DNTP Pools to Maintain Genome Stability DNA Repair. 08, 2016 | Pubmed ID: 27311542 PrimPol-A New Polymerase on the Block Molecular & Cellular Oncology. Apr-Jun, 2014 | Pubmed ID: 27308331 dNTPase SAMHD1 ile Küçük Molekül Etkileşimini Araştırmak için Yüksek Verimli Enzime Bağlı Aktivite Testi Miriam Yagüe-Capilla1, Sean G. Rudd1 1Science for Life Laboratory, Department of Oncology-Pathology, Karolinska Institutet JoVE 62503 Biochemistry
dNTPase SAMHD1 ile Küçük Molekül Etkileşimini Araştırmak için Yüksek Verimli Enzime Bağlı Aktivite Testi Miriam Yagüe-Capilla1, Sean G. Rudd1 1Science for Life Laboratory, Department of Oncology-Pathology, Karolinska Institutet JoVE 62503 Biochemistry